Merck Sharpe and Dohme study highlights efficacy of Rotateq

Merck Sharpe and Dohme has highlighted new data which underlines the efficacy of Rotateq, its rotavirus vaccine designed for use in developing nations.

According to a study published in the Lancet, the treatment has been able to reduce rates of severe rotavirus gastroenteritis by 48 per cent in infants evaluated in poorer Asian nations during a two-year follow-up study.

It was also shown to have effected a 39 per cent reduction in African nations such as Ghana, Kenya and Mali.

Dr Mark Feinberg, vice-president of medical affairs and policy for Merck’s vaccines division, described this as important progress towards a leading public health goal.

He added: “Merck is committed to advancing global health by improving access to Rotateq in areas most affected by the severe consequences of rotavirus disease.”

Earlier this month, Merck Sharpe and Dohme published positive data from two phase III trials of the hepatitis C treatment boceprevir, which it hopes will support the treatment’s case for regulatory approval.